Drug intelligence / Profile preview

Multi-Gyn FloraFem

Development stage: Unknown
Lead developer: Karo Healthcare
Administration: Topical, Vaginal

Overview

Multi-Gyn FloraFem is a prebiotic vaginal gel developed by Karo Pharma AB for the treatment of vulvovaginal candidiasis (vaginal yeast infection). It is designed to relieve symptoms such as itching, irritation, odor, and discharge by supporting the natural vaginal ecosystem and restoring microflora balance. Unlike conventional antifungal drugs, it does not employ a direct fungicidal mechanism but rather a prebiotic approach to modulate the vaginal microbiome. It is classified as a medical device and has been evaluated in clinical trials (e.g., NCT05552378) for both the treatment of active infection symptoms and the prevention of recurrent episodes.

Brand names: Multi-Gyn FloraFem
Other names: FloraFem

Beyond the preview

Go deeper on Multi-Gyn FloraFem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multi-Gyn FloraFem.

Explore the full profile